Overview of the PET.CT Molecular Imaging Program
Cleveland Clinic Abu Dhabi’s offers PET.CT Molecular Imaging through its program in Al Ain which supports advanced imaging diagnostics in specialties such as oncology, cardiology, and neurology.
PET.CT imaging uses injections of small quantities of a radiotracer (radioactive dye) to produce three-dimensional, functional and anatomical images of an organ or the entire body. This important technology allows physicians to make much more accurate assessments of disease status and to create personalized, Patients First treatment plans.
Highly knowledgeable physicians care for patients in a state-of-the-art facility equipped with a PET.CT scanner and a Cyclotron, a machine that produces radiotracers for molecular imaging. These enable the PET.CT Molecular Imaging. Program to realize what are among the most advanced imaging studies in the region.
What We Treat
PET.CT molecular imaging is an invaluable, noninvasive diagnostic aid for physicians. It is instrumental in early detection and treatment planning for patients with conditions such as cancer, cardiovascular disease (CVD), neurological disease, and other illnesses.
A cutting-edge technology, PET.CT provides information that other imaging tests do not, enabling physicians to identify diseases in their early stages and to determine the exact location of the problem. Because nuclear medicine scans provide imaging at the cellular and molecular level, PET.CT imaging can also assist in diagnosing an issue before symptoms occur, or before the condition can be detected with other kinds of tests.
PET.CT imaging is used to diagnose and manage a wide range of conditions, including:
- Coronary heart disease
- Brain disorders (including epilepsy and Alzheimer’s disease)
Diagnosis & Treatment with PET.CT Molecular Imaging
Patients are typically referred to the PET.CT Molecular Imaging Program by a specialist physician. Referring specialists may be cardiologists at Cleveland Clinic Abu Dhabi’s Heart & Vascular Institute, neurologists at the Neurological Institute, oncologists, or other physicians.
Prior to a PET.CT imaging study, the patient receives an intravenous injection with a radioactive dye, called a radiotracer, which either accumulates in a target organ or attaches to specific cells. The PET.CT scanning equipment is then able to detect the radiotracer and create pictures that show its distribution in the body. By looking at the way the radiotracer is distributed, physicians can evaluate the function of tissues and organs.
PET.CT imaging tests and procedures performed by expert physicians in the PET.CT Molecular Imaging Program include:
- Absolute blood flow imaging (for coronary heart disease, pre-surgical evaluation in epilepsy, early diagnosis of dementia, bone tumors, and other cancers)
- Tests for myocardial (heart muscle) perfusion (blood flow), viability, and inflammation or infection
- Assessing the spread of bone cancer
- Identifying causes of bone pain
- Evaluation of epilepsy and Alzheimer’s disease
- Evaluation of cancer
Following the study, the radiologist generates a complete report for the physician who referred the patient.
PET.CT Molecular Imaging Program Caregivers
The PET.CT Molecular Imaging Program at the Imaging Institute is composed of Western-board or equivalent certified physicians and other team members who possess an exceptional depth of expertise in the field. Specialists are cross-trained in radiology, nuclear medicine, and nuclear cardiology. Caregivers involved in patient care for this program are:
- Technologists specializing in nuclear medicine
- Certified nurses trained to work with patients undergoing nuclear medicine studies
Copyright © Cleveland Clinic Abu Dhabi LLC 2017